About Sung Lee
Sung Lee is EVP, Chief Financial Officer at Cytokinetics.
Form D filings name Sung Lee as an executive officer and director at Encentrio Therapeutics.
Sung Lee reports to the SEC as a director or officer of 4 public companies, including Tango Therapeutics (TNGX), Vir Biotechnology (VIR) and Sangamo Therapeutics (SGMO).
Sung Lee first appears on SEC filings in 2019.
Experience
This experience comes from SEC filings. The years are when the filings name Sung Lee in the role, so the role may have started earlier or lasted longer.
CI
Cytokinetics Inc.
EVP, Chief Financial Officer
2024 – 2026 · Public company (CYTK)
TI
Tango Therapeutics, Inc.
Director
2026 · Public company (TNGX)
VI
Vir Biotechnology, Inc.
EVP & Chief Financial Officer
2023 – 2024 · Public company (VIR)
SI
Sangamo Therapeutics, Inc.
EVP, Chief Financial Officer
2019 – 2020 · Public company (SGMO)
Key Colleagues at Startups
The people Sung Lee works with at each company, as listed on that company's latest Form D.
Encentrio Therapeutics, Inc. · Form D, Apr 3, 2023
TH
Thomas Hecht
Director
GS
George Scangos
Director
JN
Johanna Friedl-Naderer
Director
NS
Natascha Schill
Chief Executive Officer and director
VV
Vanina de Verneuil
Executive officer